234 related articles for article (PubMed ID: 32808557)
1. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review.
Kim JW; Jung JY; Suh CH
Expert Opin Biol Ther; 2021 Jan; 21(1):57-73. PubMed ID: 32808557
[TBL] [Abstract][Full Text] [Related]
2. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.
García-Beloso N; Altabás-González I; Samartín-Ucha M; Gayoso-Rey M; De Castro-Parga ML; Salgado-Barreira Á; Cibeira-Badia A; Piñeiro-Corrales MG; González-Vilas D; Pego-Reigosa JM; Martínez-López de Castro N
Br J Clin Pharmacol; 2022 Feb; 88(4):1529-1550. PubMed ID: 34622969
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
Chingcuanco F; Segal JB; Kim SC; Alexander GC
Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory diseases: Integrating biosimilars into clinical practice.
Feldman SR
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S16-21. PubMed ID: 26058549
[TBL] [Abstract][Full Text] [Related]
5. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars: implications for rheumatoid arthritis therapy.
Cohen S; Kay J
Curr Opin Rheumatol; 2017 May; 29(3):260-268. PubMed ID: 28306596
[TBL] [Abstract][Full Text] [Related]
7. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars in Dermatology: Current Situation (Part II).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):550-4. PubMed ID: 26049964
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
Zhang J; Sridhar G; Barr CE; Eichelberger B; Lockhart CM; Marshall J; Clewell J; Accortt NA; Curtis JR; Holmes C; McMahill-Walraven CN; Brown JS; Haynes K
J Manag Care Spec Pharm; 2020 Apr; 26(4):417-490. PubMed ID: 32223608
[TBL] [Abstract][Full Text] [Related]
11. Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Oct; 31(5):439-446. PubMed ID: 28752242
[TBL] [Abstract][Full Text] [Related]
12. Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab.
Feagan BG; Lam G; Ma C; Lichtenstein GR
Aliment Pharmacol Ther; 2019 Jan; 49(1):31-40. PubMed ID: 30411382
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview.
Song YJ; Nam SW; Suh CH; Choe JY; Yoo DH
Expert Opin Drug Metab Toxicol; 2023; 19(11):751-768. PubMed ID: 37842948
[TBL] [Abstract][Full Text] [Related]
14. [Use of biosimilars in the treatment of rheumatoid arthritis : An overview].
Morf H; Witte T
Z Rheumatol; 2022 Mar; 81(2):110-117. PubMed ID: 34825948
[TBL] [Abstract][Full Text] [Related]
15. The global landscape on interchangeability of biosimilars.
Rathore AS; Stevenson JG; Chhabra H; Maharana C
Expert Opin Biol Ther; 2022 Feb; 22(2):133-148. PubMed ID: 33567923
[TBL] [Abstract][Full Text] [Related]
16. Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review.
Yin Y; McDermott C; Lockhart C
J Manag Care Spec Pharm; 2023 Sep; 29(9):985-998. PubMed ID: 37610110
[No Abstract] [Full Text] [Related]
17. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases.
Rinaudo-Gaujous M; Paul S; Tedesco ED; Genin C; Roblin X; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2013 Oct; 38(8):914-24. PubMed ID: 24001128
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.
Nast A; Rosumeck S; Seidenschnur K
J Dtsch Dermatol Ges; 2015 Apr; 13(4):294-300. PubMed ID: 25819235
[TBL] [Abstract][Full Text] [Related]
19. The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis.
Braun J; Kay J
Expert Opin Drug Saf; 2017 Mar; 16(3):289-302. PubMed ID: 28068848
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
